Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee96f5c009fb9e4d1d72f0a4e32340b1 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
filingDate |
2012-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bb039c9ae1e59ffbd03520b524019c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d74b54662ebc57decfd91fe0ab314ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f515d8e87706dc686e12059fb8a25f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8383aa72b24e08cdc00ce9de7c84c878 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cac9abee1d8e4b7ffa5f73d6bc9543df |
publicationDate |
2016-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2995623-A1 |
titleOfInvention |
Mutations in the epidermal growth factor receptor gene |
abstract |
The invention relates to a new identified mutation in the epidermal growth factor receptor gene, leading to an amino acidic change which highly correlates with the resistance to a therapy regimen comprising cetuximab and the sensitivity to a therapy regimen comprising panitumumab. The invention includes peptide sequences, primers and probes to detect such a mutation, as well as kits for predicting the response of a subject to a therapy regime comprising cetuximab and/or panitumumab. In particular, the invention is useful in the therapy regimen applicable to metastasic colorectal cancer and to head and neck cancer. |
priorityDate |
2011-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |